BRISTOL-MYERS SQUIBB CO (BMY:NYSE)
$63.43 -0.32 (-0.502%)
Analysed BRISTOL-MYERS SQUIBB CO (BMY:NYSE) News Sources
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
10-09-2026
yahoo.com
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More.
10-09-2026
yahoo.com
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
11-09-2026
yahoo.com
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
10-09-2026
yahoo.com
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
08-09-2026
biopharmadive.com
A new immuno-oncology play raises $225M for a next-generation drug
09-09-2026
biopharmadive.com
SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026
09-09-2026
yahoo.com
Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?
09-09-2026
yahoo.com
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
10-09-2026
yahoo.com
Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline
11-09-2026
yahoo.com
What is the current price of BRISTOL-MYERS SQUIBB CO (BMY:NYSE)?
The current price of BRISTOL-MYERS SQUIBB CO (BMY:NYSE) is $63.43.
BRISTOL-MYERS SQUIBB CO (BMY:NYSE) absolute price change since previous trading day?
The absolute price change of BRISTOL-MYERS SQUIBB CO (BMY:NYSE) since the previous trading day is $-0.32.
BRISTOL-MYERS SQUIBB CO (BMY:NYSE) percentage price change since previous trading day?
The percentage price change of BRISTOL-MYERS SQUIBB CO (BMY:NYSE) since the previous trading day is -0.502%.
What is the most recent average sentiment score for BRISTOL-MYERS SQUIBB CO (BMY:NYSE)?
The most recent average sentiment score for BRISTOL-MYERS SQUIBB CO (BMY:NYSE) is 46 out of 100.
What is the most recent average sentiment for BRISTOL-MYERS SQUIBB CO (BMY:NYSE)?
The most recent sentiment for BRISTOL-MYERS SQUIBB CO (BMY:NYSE) is .
SEC-8K** Filing Available For BRISTOL-MYERS SQUIBB CO (BMY:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.